Pharmaceutical market fails pregnant women; and more

Follow us on Twitter

In a clinical trial published this week in PLoS Medicine, Charles Sawyers and colleagues looked at the safety of a drug called rapamycin in a selected group of patients who were undergoingsurgery after recurrence of glioblastoma (a highly malignant tumor of the brain).

In a related research in translation article about the implications of the research, Robert J. Weil, who was not involved in the trial, suggests that the study points the way “toward rational design of therapy for stratified groups of patients who share common molecular features” and a future that allows “cancer researchers and clinicians to reach toward the holy grail of individualized therapy”-Public Library of Science

Receive HULIQ News in Email:

Subscribe in a reader